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Disclosure
• Speakers’ Bureau:  BMS, Merck. 
• Advisory Meetings:  Abbvie, Genentech.  
Objectives
• Learn immune checkpoint inhibitor’s 
(immunotherapy) mechanism of action.
• Recognize the differences in immunotherapy 
side effects vs chemotherapy side effects.
• Learn initial management of immunotherapy 
side effects. 
• Learn about the resources available for 
immunotherapy side effect management. 
What is Immunotherapy?
• A type of therapy that affects the immune 
system to fight cancer.  
• Many different types of immunotherapy:  
vaccines, small molecule compounds, 
monoclonal antibodies, gene therapies, 
cellular therapies.
• For the purpose of this talk, I will use the 
terms “Immunotherapy” and  “Immune 
Checkpoint Inhibitors” interchangeably.  

Immune Checkpoint Inhibitor 
Mechanisms of Action
Suzanne L. Toaplian, et al.  Nature Reviews Cancer volume 16, pages 275–287 (2016)
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Courtesy of Evan J Lipson, MD
Research to Practice
FDA approved Agents and Indications
• Ipilimumab (CTLA-4 ab)
• Cemiplimab-rwlc, Nivolumab, Pebrolizumab
(PD-1 ab)
• Atezolizumab, Avelumab, Durvalumab (PD-L1 
ab)
• More than 30 FDA approved Indications across 
multiple cancer types, and GROWING! 
Immunotherapy is better 
tolerated   
Severe Side Effects are Rare 
but Do Occur
Immune side effects can involve Any 
Organ
Immune side effects are usually delayed 
in onset, unlike chemotherapy
Journal of Clinical Oncology 30(21):2691-2697.
Colitis was the most common serious side effect but 
Myocardititis was most lethal by percentage
American Society of Clinical 
Oncology(ASCO) 2018 Guideline
• Education prior to and throughout and after treatment. 
• High level of suspicion for immune side effects
• Grade 2 toxicity:  hold immunotherapy and start 
corticosteroid (0.5-1mg/kg). 
• Grade 3 toxicity:  hold and start higher dose corticosteroid (1-
2mg/kg IV).  Consider adding infliximab or other 
immunomodulators if no improvement in 48-72hrs.
• Grade 4 toxicity: similar to grade 3 toxicity management plus 
permanent discontinuation.  
Important to Slowly Taper 
Corticosteroid!
• Need to taper prednisone slowly over 4-6 
weeks to prevent relapse. 
• Depending on the initial severity of immune 
side effect, Immunotherapy may be resumed 
when side effects improve to grade 1 and daily 
prednisone dose of <10mg/day
Patient Education Video
Courtesy of Enza Nguyen, RN, MSN, ANP-BC
Courtesy of Enza Nguyen, RN, MSN, ANP-BC
Include in the Past Medical History 
Section of Medical Record
• Immune-related adverse events can occur 
even months after treatment has been 
discontinued.
• Part of the differential diagnosis when 
patients get sick.   
Free Tools for immune side effect 
management: NCCN Guidelines
www.nccn.org
Free Tools for immune side effect 
management: ONCOASSIST
www.oncoassist.com
Conclusion
• Immune Checkpoint Inhibitors have revolutionized 
Cancer treatment, and the use is expected to grow 
over time. 
• Immune side effects are usually manageable with 
prompt recognition and corticosteroid use. 
• Immune side effects can occur even after treatment 
as been discontinued.
• Adherence to guidelines optimize immune side 
effects management.  
